NMN and Longevity: Efficacy, Safety, and Evidence

Nicotinamide mononucleotide (NMN) does increase nicotinamide adenine dinucleotide (NAD⁺) levels in human blood, but there is no evidence that it slows aging or prolongs human life. This is a key distinction that is often lost in the literature on NMN: the biochemical effect has been confirmed, while the clinical effect on aging remains unproven. The largest systematic review from 2026 included 33 human intervention studies and concluded that NAD⁺ precursor drugs reliably alter NAD⁺-related biomarkers, but the results for metabolism, vascular health, physical function, and other clinically relevant outcomes remain mixed. [1]

The most recent meta-analysis of NMN itself, published July 10, 2026, included 15 randomized trials. These trials used doses ranging from 250 to 2000 mg daily for periods ranging from 14 days to 24 weeks. NMN did not increase the overall incidence of adverse events, serious adverse events, or liver function tests in the short term, but no significant effect was found on body weight, body mass index, fasting glucose, glycated hemoglobin, lipid profile, or systolic blood pressure. [2]

Therefore, the statement "NMN works" requires clarification. If by "work" we mean increasing NAD⁺, then yes. If by "work" we mean weight loss, improving blood sugar or cholesterol, then there is no convincing overall effect yet. If by slowing biological aging, then there is no proven evidence. If by increasing human lifespan, then there is no such clinical data at all. Not a single completed randomized study has followed people long enough to determine the effect of NMN on lifespan or the incidence of major age-related diseases. [3]

This doesn't render NMN hopeless. Animal studies and isolated small clinical trials provide interesting signals—from muscle insulin sensitivity to certain gait and sleep parameters. But in modern evidence-based medicine, a signal becomes a recommendation only after it is confirmed by independent, sufficiently large, and long-term studies with clinically significant results. NMN has not yet reached this stage.

What is NMN and why is it linked to aging?

NMN (nicotinamide mononucleotide) is an intermediate in the NAD⁺ formation system. Nicotinamide adenine dinucleotide is essential for virtually every cell: it participates in oxidation-reduction reactions and energy metabolism, and serves as a substrate for a number of enzymes involved in DNA repair, cellular signaling, and metabolic regulation. [4]

Interest in NMN arose after studies demonstrated changes in NAD⁺ metabolism during aging and certain diseases. Animal experiments demonstrated that increasing NAD⁺ availability via its precursors can influence numerous physiological processes. This led to a logical hypothesis: if age-related decline in NAD⁺ is part of the biology of aging, restoring its levels could potentially mitigate some of the age-related functional changes. [5]

However, there is a significant gap between this hypothesis and proven therapy. Even if NAD⁺ levels do change with age, this does not prove that their decline is an independent cause of aging in all tissues or that artificially increasing NAD⁺ above a certain level will provide additional benefit. Current reviews clearly indicate that it remains to be established to what extent NAD⁺ levels in the blood and individual tissues predict disease and whether their restoration improves clinical outcomes in humans. [6]

Therefore, it's better to think of NAD⁺ not as the "fuel of youth" that simply depletes with age, but as one of the body's many metabolic nodes. It can be modified, but targeting one node doesn't necessarily reverse the entire aging process.

NMN does increase NAD⁺ in humans

This is the most well-documented part of the NMN story. Several randomized studies have shown increases in NAD⁺ or related metabolites in the blood after oral administration of NMN. In a 2023 study of 80 adults, NAD⁺ concentrations increased with 300, 600, and 900 mg of NMN per day for 60 days. [7]

A 2025 meta-analysis of 12 studies with 513 participants also confirmed a statistically significant increase in blood NAD⁺ levels. However, the authors found issues with the quality of the evidence: all included studies had either some concerns about bias or a high risk of such bias. Most clinically relevant indicators of carbohydrate and lipid metabolism did not change significantly. [8]

In 2026, a particularly interesting study appeared, directly comparing NMN for the first time with another known NAD⁺ precursor, nicotinamide riboside. In a randomized trial of 65 healthy individuals, two weeks of NMN and nicotinamide riboside resulted in comparable increases in circulating NAD⁺. The study also showed that the pathway for the conversion of these substances may be more complex than the simple "swallow NMN and it enters the cells whole" model: gut microbiota and the conversion of precursors to nicotinic acid likely play a significant role. The study was funded by and performed with the participation of Nestlé employees, which should be taken into account when evaluating the results. [9]

This last result is particularly helpful for understanding the topic. Commercial advertising sometimes contrasts NMN with other forms of vitamin B3 based on the supposed "direct delivery" of NMN to cells. New human data show that the actual pharmacokinetics are significantly more complex and involve conversion of the substance even before systemic NAD⁺ increases. [10]

Increasing NAD⁺ does not necessarily mean longer life

This is the central limitation of the entire evidence base. Aging studies often begin by measuring a biomarker—a parameter that reflects a specific biological process. An increase in NAD⁺ confirms that NMN interacts with its intended target, but it doesn't answer the question of whether it will lead to longer life or reduced illness.

To prove an effect on longevity, it would be necessary to demonstrate a reduction in mortality or, at a minimum, a convincing reduction in the incidence of age-related diseases, disability, or functional decline in long-term studies. Existing NMN trials typically last several weeks or months. The most recent meta-analysis from 2026 included studies with a maximum duration of 24 weeks. [11]

Six months is enough to see changes in NAD⁺, glucose, or blood pressure. But it's completely insufficient to determine whether the number of heart attacks, strokes, dementia cases, cancer cases, or deaths has decreased over 10-20 years.

This is why the conclusion of the 2026 Ageing Research Reviews systematic review is rather cautious: the biological activity of NAD⁺ precursors in humans has been proven, but the effectiveness as an anti-aging or health intervention remains uncertain; longer-term and statistically powerful randomized trials with clinically relevant endpoints are needed. DOI of the review: 10.1016/j.arr.2026.103057. [12]

What NMN studies in humans have actually shown

The modern picture looks most conveniently not as “works/doesn’t work,” but as several levels of evidence.

Result	What is known by September 2026	How convincing
Increased NAD⁺ in the blood	Has been found repeatedly in randomized trials	The most convincing effect
Safety for weeks to months	No significant signal of harm was found in studies up to 24 weeks	Relatively convincing for a short period
Insulin sensitivity	A positive result was obtained in one small specific group, but meta-analyses do not show a consistent overall effect	Uncertain
Glucose and glycated hemoglobin	In pooled studies, there is usually no significant improvement.	Benefits not confirmed
Cholesterol and triglycerides	There is no convincing overall improvement.	Benefits not confirmed
Body weight	A 2026 meta-analysis found no significant effect.	Benefits not confirmed
Physical function	There are positive secondary results in some small studies	Preliminary
Sleep and fatigue	Some small studies provide positive signals	Preliminary
Blood pressure	Minor changes in individual indicators are possible	Clinical significance has not been established.
Biological age	Separate algorithms and surrogate indicators were used	Real rejuvenation has not been proven
Life expectancy	There are no studies on humans.	Unknown
Prevention of dementia, cancer, and heart attack	Not proven	Unknown

Sources of summary assessment: systematic reviews and meta-analyses from 2024–2026. [13]

This table clearly demonstrates why NMN appears simultaneously compelling biochemically and uncertain clinically. The closer the indicator is to NAD⁺ metabolism itself, the more consistent the effect. The further we move into real-world human health, the weaker and more inconsistent the results.

Does NMN improve blood sugar and insulin sensitivity?

For the general population, no convincing metabolic effect has yet been demonstrated. Interest in this area has increased significantly after a small 2021 Science study involving postmenopausal women with prediabetes and overweight or obesity. After ten weeks of NMN, they showed improved skeletal muscle insulin sensitivity, measured by a high-precision hyperinsulinemic euglycemic clamp. DOI: 10.1126/science.abe9985. [14]

The study was interesting precisely because it measured not only standard fasting glucose, but also the physiological muscle response to insulin. However, the study was small: 13 women received NMN, 12 received a placebo. Criticism of the differences in baseline liver fat content between the groups was later published, but the study's authors responded that baseline muscle insulin sensitivity was comparable and the main result remained significant. [15]

Subsequent pooled data did not support a universal improvement in glucose metabolism. A meta-analysis of eight randomized trials involving 342 mostly healthy middle-aged and older adults found no significant effect of NMN on fasting glucose, insulin, glycated hemoglobin, insulin resistance index, or lipid profile. [16]

A larger 2025 meta-analysis with 513 participants came to a similar conclusion: NAD⁺ increases, but most clinically interesting metabolic markers do not. [17]

This is a good example of why the results of one study cannot be automatically generalized. NMN may potentially be more beneficial for certain metabolic phenotypes than for the healthy population, but these groups first need to be identified and their effects confirmed in independent studies.

Does NMN help you stay fit?

There are positive signals, but they are not yet consistent enough to consider NMN a proven means of preserving muscle function.

In a 2023 study of 80 healthy middle-aged adults, participants taking 300-900 mg of NMN daily for 60 days showed a greater increase in six-minute walk distance than the placebo group. Blood NAD⁺ levels also increased. However, some of the study's authors were employees of companies involved in NMN production, and the study was small and short-lived. [18]

In another double-blind study, 60 elderly people took 250 mg of NMN for 12 weeks. The primary outcome measure, the rapid step test, did not differ significantly between NMN and placebo. Positive results emerged among secondary outcomes: a four-meter walk was completed faster, and some sleep measures improved. Three of the authors were employees of Meiji Holdings. [19]

The distinction between the primary and secondary endpoints is crucial here. The study is pre-designed primarily for the primary outcome. Positive secondary outcomes are interesting and can serve as the basis for a subsequent study, but they provide significantly weaker confirmation of efficacy than a reproducible effect on the pre-selected primary endpoint.

Therefore, there is no basis for using NMN instead of strength training, physical activity, or a balanced diet. The evidence for these interventions in maintaining physical function is incomparably stronger.

Does NMN improve sleep?

Some studies have found changes in sleep parameters, but NMN is not yet a proven treatment for insomnia or age-related sleep disorders.

In a randomized trial of 108 elderly Japanese adults, 250 mg of NMN per day was administered at different times of day for 12 weeks. Some positive results were obtained for sleepiness, fatigue, and physical function, but sleep measures did not show a universal improvement across all scales. [20]

A 2024 study of 60 older participants also found improvements in some secondary measures of the Pittsburgh Sleep Quality Index, while the primary outcome of the study was physical function.[21]

These results are interesting for further study, but do not allow NMN to be recommended as a treatment for insomnia. If someone is experiencing poor sleep, it is much more useful to first determine the specific cause—sleep patterns, apnea, medications, pain, depression, or another condition.

Is it true that NMN reduces "biological age"?

This hasn't been proven yet. The best-known indicator comes from a study of 80 middle-aged people using the Aging.Ai 3.0 algorithm based on blood tests. After 60 days, the calculated indicator increased in the placebo group, while it remained relatively stable in the NMN groups. [22]

The problem is that the "blood age" calculated by the algorithm is a surrogate indicator. For an intervention to be considered rejuvenating, it must be proven that a change in this algorithm corresponds to a reduction in morbidity, functional decline, or mortality. This has not been demonstrated for NMN.

Furthermore, in this study, biological age was a secondary endpoint, the study lasted only 60 days, and some of the authors were affiliated with the manufacturing companies. This does not invalidate the study, but it significantly limits the strength of the conclusion. [23]

Therefore, the statement "NMN reduces biological age" sounds considerably more certain than the data suggests. It would be more accurate to say that in one small study, NMN altered a specific predicted aging biomarker; whether this translates to a true slowing of aging is unknown.

What is known about the lifespan of animals?

It was animal data that made NMN famous. In a 2016 seminal study in Cell Metabolism, normal mice were given NMN for 12 months. The supplement reduced a number of age-related physiological changes, affecting energy metabolism and physical activity, insulin sensitivity, lipid profile, eye function, and several other indicators. DOI: 10.1016/j.cmet.2016.09.013. [24]

However, this study primarily examined healthy functioning, not evidence of increased lifespan. In popular retellings, these concepts are often conflated: if old mice become physiologically better, it seems they must necessarily live longer. The study did not establish this. [25]

In 2024, a preliminary study in mice showed that long-term NMN treatment reduced frailty and, in females but not males, was associated with an increase in median lifespan of approximately 8.5%. However, the source remains a preliminary publication and has not undergone the usual peer-review process for a final journal article, so caution should be exercised when using this result as evidence of lifespan extension, even in mice.[26]

And most importantly, extending the lifespan of a laboratory mouse doesn't predict how much longer a human will live. Doses, lifespans, metabolism, causes of death, and the biology of aging itself all vary.

Why do mouse results translate so poorly to human longevity?

Laboratory mice live for several years, so exposure can begin at a certain age and be observed almost until the end of their life. A similar study in humans would require decades.

Furthermore, laboratory animals are much more genetically homogeneous than humans and are kept in controlled conditions. Humans have significantly different hereditary backgrounds, diets, medications, physical activity, illnesses, sleep, and social environments. What corrects one dysfunctional pathway in a mouse may be much less significant within the complex human physiology.

A 2026 systematic review illustrates this gap well: in 80 rodent studies, increasing NAD⁺ often improved metabolic, mitochondrial, inflammatory, and functional measures, whereas 33 human studies yielded significantly less consistent clinical results. [27]

It is this translational gap that is currently the main obstacle to the claim that NMN is a longevity drug.

Is NMN safe?

Short-term studies look quite favorable, but long-term safety is unknown.

A 2026 meta-analysis included doses of 250-2000 mg daily for 14 days to 24 weeks. Compared with control groups, no increase in overall adverse events, serious adverse events, treatment discontinuations due to adverse events, or significant increases in alanine aminotransferase and aspartate aminotransferase, enzymes used to assess liver function, was found.[28]

This is encouraging, but the statement "NMN is safe" without specifying a timeframe would be inaccurate. Rare side effects may not appear in several hundred participants, and the potential consequences of long-term exposure cannot be determined from studies lasting only a few months.

There is particularly limited data for pregnancy and breastfeeding, long-term use in young healthy individuals, and some groups with chronic diseases. The European Food Safety Authority, in its 2026 assessment, considered a specific β-NMN product of at least 99% purity in doses up to 300 mg per day for adults only, excluding pregnant and breastfeeding women. [29]

This further demonstrates why one cannot automatically transfer the conclusion that "it was well tolerated in the short term" to ten years of daily use for longevity.

Is there a risk to the liver?

Available human data do not yet show a significant signal of liver damage. A 2026 meta-analysis found no significant increase in alanine aminotransferase or aspartate aminotransferase compared to controls. [30]

The European Food Safety Authority also reviewed laboratory data and human studies of specific highly purified β-NMN. Trials of up to 900 mg per day for 60 days and 250 mg for 24 weeks revealed no significant substance-related adverse effects, supporting the conclusion that the specific product is safe at the proposed use of up to 300 mg per day. [31]

However, this does not mean that any commercial NMN is safe for the liver at any dose. The assessment of a specific substance with a certain purity does not automatically apply to products of unknown composition or to long-term use.

What about cancer?

There is currently no evidence that standard doses of NMN tested cause cancer in humans, but existing clinical trials are too short and small to reliably assess such an outcome.

The reason for caution is biological. NAD⁺ is necessary for normal cells for energy metabolism and DNA repair, but tumor cells also utilize NAD⁺ metabolic systems. Therefore, increasing NAD⁺ availability cannot be automatically classified as either an antitumor or procarcinogenic intervention in humans without appropriate research.

The mere fact that participants took NMN for several weeks without serious complications does not indicate the risk of a disease with a long-lasting latency period. This is especially important when evaluating long-term prophylactic use in healthy individuals: the standard of evidence here must be higher than for short-term treatment of a specific disease.

It is prudent not to initiate NMN on your own in a person with active cancer or receiving anticancer therapy: there is insufficient clinical data to assess potential interactions with specific treatments.

How much NMN was taken in the studies?

Human studies have used a very wide range—approximately 250–2000 mg per day—but this does not mean that this range is the recommended dosage for longevity. A recent meta-analysis describes the amounts studied in this way; the maximum duration was 24 weeks. [32]

Some studies have used 250 mg daily for 12 weeks, 300-900 mg for 60 days, or a specially formulated form of NMN in amounts up to 2000 mg daily for short periods.[33]

Increasing the dose sometimes leads to a more pronounced increase in blood NAD⁺, but there is no proven relationship between "the higher the NAD⁺, the greater the clinical benefit." For example, an increase in a biochemical indicator does not guarantee improvement in glucose, physical function, or any other outcome.

Therefore, there is no scientifically proven “anti-aging dose of NMN” today.

What does the European Safety Assessment 2026 mean?

In May 2026, the European Food Safety Authority published a landmark opinion on β-NMN, and on July 8, the document was supplemented. The expert committee found chemically synthesized β-NMN of at least 99% purity to be safe under the proposed conditions of use—up to 300 mg per day in dietary supplements for adults, excluding pregnant and lactating women. It also confirmed that NMN contains bioavailable nicotinamide as a source of vitamin B3. DOI of the opinion: 10.2903/j.efsa.2026.10007. [34]

But this is a safety assessment of a specific new food ingredient, not a validation of NMN as a life-extending agent. The experts did not conclude that 300 mg slows aging, improves health, or is an optimal preventative dose. [35]

In the European Union, NMN with a purity of 95-99% was classified as a "novel food" in 2022, as no confirmed history of its use prior to May 15, 1997, was found. A separate assessment and authorization procedure applies to novel foods. In 2025, new applications for β-NMN were submitted to the European Commission. [36]

This nuance is important for consumers: regulatory safety assessment and proof of anti-aging effectiveness are completely different things.

What's Happening with NMN in the US?

NMN's regulatory history in the US is unusual. In 2022, the US Food and Drug Administration (FDA) took the position that NMN should be excluded from the definition of a dietary supplement due to research into the substance as a potential drug.

On September 29, 2025, the agency revised its interpretation and concluded that NMN was not excluded from the legal definition of a dietary supplement because evidence was provided of its sale in the United States as a supplement prior to the effective date of the relevant Investigational New Drug Authorization (INDA).[37]

However, this decision is sometimes incorrectly presented as "the Food and Drug Administration has approved NMN." This means something different: NMN is not exempt from the category of dietary supplements under the relevant legal provisions. This is not an endorsement of NMN as an anti-aging drug or a confirmation of its effectiveness or safety for life extension.

Therefore, the presence of a product on the US market cannot be used as evidence that the anti-aging effect has passed regulatory review.

NMN or Nicotinamide Riboside: Is There a Winner?

There is no evidence that NMN is better than nicotinamide riboside for prolonging human life.

Both substances are precursors of NAD⁺. In a head-to-head comparison study in 2026, two weeks of NMN and nicotinamide riboside administration comparable increases in circulating NAD⁺ concentrations in healthy volunteers. [38]

This is particularly interesting because promotional materials often try to portray one predecessor as fundamentally more "direct" or "potent." At the blood level, the new study found no such clear superiority for NMN.

But the opposite conclusion—"they are identical in every respect"—would also be premature. Metabolism, tissue distribution, and long-term effects may differ. The study lasted only 14 days and primarily examined metabolism, not aging. [39]

Therefore, the choice between NMN and nicotinamide riboside cannot currently be based on a proven difference in longevity: no one has established such a difference.

NMN and intravenous NAD⁺ are not the same thing

NMN is taken as a precursor from which the body produces NAD⁺. The longevity industry offers intravenous infusions of NAD⁺ itself, sometimes with claims of increased energy, rejuvenation, or improved brain function.

A 2026 systematic review specifically searched for studies of parenteral NAD⁺ and found no suitable controlled clinical outcome studies for anti-aging or health benefits.[40]

Therefore, data on oral NMN cannot be used as evidence for the effectiveness of intravenous NAD⁺ - these are different interventions with different pharmacokinetics.

Why NAD⁺ blood levels can't be considered a "youth scale"

The most attractive commercial logic seems to be this: NAD⁺ decreases with age → NMN increases NAD⁺ → therefore, a person becomes biologically younger. This chain is missing several links in the evidence.

First, the body consists of many tissues, in which NAD⁺ metabolism may vary. Whole blood concentrations do not automatically determine NAD⁺ levels in the brain, liver, muscle, or heart.

Second, even a detected increase in a particular tissue does not mean that the initial level was pathologically low or that further increases will necessarily improve function.

Third, the biological measure must be validated against outcomes that are important to humans. It has not yet been proven that a specific increase in NAD⁺ after NMN predicts lower mortality, dementia, cardiovascular disease, or disability. Systematic reviews in 2025–2026 demonstrate precisely this gap: the biomarker responds significantly more consistently than clinical measures. [41]

Therefore, measuring NAD⁺ after taking NMN to prove “rejuvenation” is not scientifically sufficient.

Why the effect may vary from person to person

One promising hypothesis is that NMN may provide greater benefit to people with a true impairment of NAD⁺-dependent metabolism than to young or metabolically healthy people.

This phenomenon is well known in medicine. If a certain physiological parameter is already within the normal range, further increasing it does not always improve the outcome. Therefore, studies involving mostly healthy volunteers may find remarkable changes in NAD⁺, but show almost no improvement in glucose, blood pressure, or physical function.

A 2021 study in women with prediabetes offers a possible example of such an effect: in a specific metabolically disadvantaged group, muscle insulin sensitivity improved. However, this is not yet sufficient to determine "who needs NMN." [42]

Future studies would likely be much more useful if, instead of simply dividing into “NMN vs. placebo in everyone,” they looked at the phenotypes of people with specific NAD⁺ metabolism disorders and determined whether biochemical correction translates into clinical benefit.

Can a healthy person take NMN for anti-aging purposes?

From a scientific perspective, this cannot yet be considered a proven preventative strategy. Short-term tolerability appears favorable, but no one has shown that long-term daily use reduces the likelihood of age-related diseases or prolongs life. [43]

Therefore, the solution differs significantly from, for example, physical activity, hypertension treatment, or smoking cessation. These interventions have known clinically significant benefits. For NMN, the main proven benefit is still much earlier in the causal chain—increased NAD⁺.

If a healthy person does decide to take NMN, it should be viewed as an experimental health supplement with unknown long-term benefits, not as a proven life-extending agent. It should especially not be used as a substitute for physical activity, a healthy diet, or treatment of blood pressure, lipids, or diabetes.

Product quality is also important. Studies were conducted with specific forms of the substance of established purity. Clinical trial results cannot be automatically transferred to any NMN-labeled bottle if the actual composition, purity, and stability of the substance are unknown.

Who should especially not experiment on their own

There are insufficient data for pregnancy and breastfeeding; therefore, the European safety assessment of specific β-NMN excludes these groups from the intended target population. [44]

Caution is also warranted in cases of active cancer, severe chronic diseases, or complex drug therapy. This is not due to the proven specific harm of NMN, but rather to the lack of sufficient research in such groups and the fact that the intervention alters a fundamental cellular metabolic pathway.

For people who want to take NMN for a specific condition—diabetes, weakness, sleep disorders, cardiovascular problems—it's especially important not to use it as a substitute for standard treatment. NMN is not an established first-line therapy for any of these indications.

What will be considered real proof of longevity?

The next stage of research must be fundamentally different. We no longer need another two-month experiment that will once again demonstrate an increase in NAD⁺ in the blood.

Truly useful studies must include hundreds or thousands of participants, last significantly longer, identify clinically important outcomes in advance, and be independently replicated. It is necessary to determine whether NMN reduces the incidence of diabetes, cardiovascular disease, frailty, cognitive decline, or other age-related conditions, or maintains functional independence.

It is precisely this lack of evidence that the 2026 systematic review highlights: existing human studies provide good support for interactions with NAD⁺ metabolism, but remain too short and heterogeneous to confidently conclude on anti-aging efficacy. [45]

Finally, a sufficiently long-term safety observation will be needed. An intervention designed for a healthy 50-year-old potentially requires years or decades of use, not months. In such a situation, six months of safety is only the first level of evidence.

What is often misunderstood

"NMN prolongs life." This has not been proven in humans. Long-term studies on human lifespan have not been conducted. [46]

"NMN has already been shown to have anti-aging effects because it increases NAD⁺." The increase in NAD⁺ is a biochemical effect, not evidence of slowing aging. Clinical results are much less consistent. [47]

"NMN improves sugar and cholesterol." Individual studies have shown positive results, but several meta-analyses do not support consistent overall improvements in glucose, glycated hemoglobin, or lipids. [48]

"The more NMN, the more rejuvenation." A dose-dependent increase in NAD⁺ does not mean a dose-dependent improvement in health, and the optimal dose for longevity has not been established. [49]

"NMN is completely safe." Short-term data are favorable, but the maximum duration of studies in a recent meta-analysis was 24 weeks. Long-term safety over many years of use is unknown. [50]

"If the regulator has recognized NMN as an acceptable supplement, it means it has been recognized as an anti-aging agent." No. Assessing the safety of a food ingredient and proving its therapeutic efficacy are different procedures. The European Food Safety Authority in 2026 assessed the safety of a specific β-NMN, not its ability to prolong life. [51]

What changed in 2026

2026 turned out to be a truly informative year for NMN, not because evidence of rejuvenation appeared, but because it became much clearer where the confirmed data ended.

First, a systematic review by Aging Research Reviews identified 113 studies of NAD⁺-targeted interventions, including 33 human studies. Its conclusion summarizes the current state of affairs well: the biological activity is compelling, the animal data are interesting, but clinical antiaging efficacy in humans is not yet established. [52]

Second, a July meta-analysis of 15 studies specifically on NMN significantly strengthened the data on short-term tolerability while simultaneously demonstrating the absence of a broad metabolic effect. This diminishes the case for portraying NMN as a one-size-fits-all treatment for weight, sugar, cholesterol, and blood pressure. [53]

Third, direct testing of NMN and nicotinamide riboside showed comparable increases in circulating NAD⁺ and revealed a likely important role for the gut microbiota in the conversion of these precursors. This complicates the old simplistic model of direct absorption of NMN as the primary explanation for its action. [54]

Finally, the European Food Safety Authority completed its evaluation of a specific, highly purified β-NMN and found it safe for the proposed use of up to 300 mg per day in adults, excluding pregnant and lactating women. This is an important regulatory safety event, but it does not make NMN a proven longevity drug. [55]

Key points from experts

Shin'ichiro Imai, MD, PhD, is the Theodore and Bertha Bryan Distinguished Professor of Environmental Medicine and Professor of Medicine and Developmental Biology at Washington University in St. Louis. His laboratory has been studying NAD⁺-dependent regulation of aging for many years and was one of the groups that demonstrated pronounced physiological effects of long-term NMN administration in mice. Recent publications by the laboratory consider NAD⁺ an important component of the systemic regulation of mammalian aging and NMN a potential tool for influencing this system. However, the research program itself is aimed at translating results from animals to humans, meaning that human clinical efficacy remains a separate question that cannot be considered resolved based on preclinical data. [56]

Samuel Klein, MD, is the William H. Danforth Professor of Medicine and Nutritional Science, chief of the Division of Nutritional Science & Obesity Medicine, and director of the Center for Human Nutrition at Washington University in St. Louis. Klein was the senior author of a 2021 randomized trial in women with prediabetes, where NMN improved skeletal muscle insulin sensitivity. This work suggests that a clinically measurable effect of NMN in humans is possible, but it was found in a very specific, small group and does not support universal metabolic or antiaging benefits. Subsequent meta-analyses did not find an overall consistent effect on glucose metabolism. [57]

Andrea Meyer is a physician and aging researcher, a professor affiliated with the Healthy Longevity Translational Research program at the National University of Singapore and the Amsterdam Aging Research Center. She participated in a randomized trial of NMN in 80 middle-aged adults, where increasing NAD⁺ was associated with some positive changes in secondary functional measures. The very design of this study illustrates the current state of the art: the biochemical result is reliably reproduced, while the functional signals still require longer-term independent verification. [58]

Frequently Asked Questions

Has NMN been proven to prolong human life?

No. There are no studies showing an increase in human lifespan or a reduction in overall mortality due to NMN. Current human trials typically last weeks or months. [59]

Does NMN really increase NAD⁺?

Yes, this is the most reproducible human effect. Increased NAD⁺ has been found in individual randomized trials and confirmed by meta-analyses. [60]

Does high NAD⁺ mean the body is younger?

No. NAD⁺ is an important metabolic indicator, but it is not a validated universal measure of biological age. It has not yet been established what increase in NAD⁺ corresponds to a specific increase in healthy lifespan.

At what age is it advisable to take NMN?

There is no scientifically established age for starting prophylactic use. Clinical studies have included various groups of middle-aged and older adults, but have not proven the need for everyone to take NMN after age 40, 50, or 60.

What is the optimal dose of NMN?

The optimal dose for longevity is unknown. Studies have used doses ranging from 250 to 2000 mg per day, but this is the range of amounts studied and is not a medical recommendation. [61]

Is there any point in taking more than 1000 mg?

There is no evidence that a higher dose improves health or longevity more. A greater increase in NAD⁺ does not necessarily translate into greater clinical benefit. [62]

Is it possible to take NMN continuously for years?

The long-term safety of this regimen has not been established. A recent meta-analysis covers studies up to 24 weeks long, so it cannot address the question of long-term use. [63]

Does NMN help you lose weight?

There is no convincing evidence. A 2026 meta-analysis found no significant reduction in body weight or body mass index. [64]

Does NMN help with insulin resistance?

One small study of women with prediabetes found improvements in muscle insulin sensitivity, but pooled data from multiple studies did not support a consistent overall improvement in carbohydrate metabolism.[65]

Does NMN improve physical endurance?

Some small studies have observed positive changes in walking tests, but the results are mixed, and in one study the primary measure of physical function did not improve. Therefore, the effect is still considered preliminary. [66]

Can NMN improve sleep?

Some small trials have found improvements in some measures of sleep and daytime function, but there is insufficient evidence to use NMN as a treatment for sleep disorders.[67]

Which is better - NMN or nicotinamide riboside?

There is no proven winner for longevity. In a 2026 head-to-head human study, both substances comparable increased circulating NAD⁺. [68]

Is NMN approved in Europe?

NMN is classified as a novel food in the European Union. In 2026, the European Food Safety Authority issued a positive safety opinion on specific β-NMN of at least 99% purity for a proposed daily intake of up to 300 mg in adults, excluding pregnant and breastfeeding women. This is a safety assessment under the Novel Food Procedure, not an approval of an anti-aging product. [69]

Has NMN been approved by the FDA?

Not as an anti-aging drug. In September 2025, the agency reversed its previous position and concluded that NMN is not excluded from the legal definition of a dietary supplement. This does not confirm its effectiveness for longevity. [70]

Is it worth taking NMN now for longevity?

From an evidence-based medicine perspective, it cannot be considered a necessary or proven intervention for life extension. If a person nevertheless decides to use it, they should understand the uncertainty of its long-term benefits and safety and not use it as a substitute for treatments with proven health benefits.

Main

NMN occupies an interesting middle ground between promising biology and unproven longevity medicine. We already know with reasonable certainty that oral NMN can increase NAD⁺ in humans and is generally well tolerated when administered over weeks to months. [71]

But the next level of evidence is significantly weaker. Individual studies find improvements in muscle insulin sensitivity, walking ability, sleep, or other measures, while meta-analyses find no consistent, broad-based effect on glucose, glycated hemoglobin, lipids, body weight, or many other metabolic indicators. [72]

And the main claim for which NMN is most often purchased—life extension—has not been directly tested in humans at all. Therefore, as of September 2026, it would be more accurate to call NMN a promising NAD⁺ precursor with confirmed biochemical activity and as-yet-undetermined anti-aging clinical efficacy, rather than a proven longevity agent. [73]